Multi-modal immune dynamics of pre-COVID-19 Kawasaki disease following intravenous immunoglobulin.

Cytokines IVIG Inflammation Kawasaki disease Proteomics T cells

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
24 Aug 2024
Historique:
received: 11 06 2024
revised: 21 08 2024
accepted: 22 08 2024
medline: 27 8 2024
pubmed: 27 8 2024
entrez: 26 8 2024
Statut: aheadofprint

Résumé

Despite progress, the molecular mechanisms underlying Kawasaki Disease (KD) and intravenous immunoglobulin's (IVIG) ability to mitigate the inflammatory process remain poorly understood. To characterize this condition, plasma proteomic profiles, flow cytometry, and gene expression of T cell subsets were investigated in longitudinal samples from KD patients and compared with two control groups. Systems-level analysis of samples in the acute phase revealed distinctive inflammatory features of KD, involving mainly Th-1 and Th-17 mediators, and unveiled a potential disease severity signature. APBB1IP demonstrated an association with coronary artery involvement (CAI) and was significantly higher in CAI+ compared to CAI- patients. Integrative analysis revealed a transient reduction in CD4+ EM T cells and comprehensive immune activation and exhaustion. Following treatment, Tregs at both frequency and gene expression levels revealed immune dynamics of recovery. Overall, our data provide insights into KD, which may offer valuable information on prognostic indicators and possible targets for novel treatments.

Identifiants

pubmed: 39186994
pii: S1521-6616(24)00458-3
doi: 10.1016/j.clim.2024.110349
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110349

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Nicola Cotugno (N)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Giulio Olivieri (G)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy.

Giuseppe Rubens Pascucci (GR)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Probiomics S.r.l., Via Montpellier 1, 00133 Rome, Italy.

Donato Amodio (D)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Elena Morrocchi (E)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Chiara Pighi (C)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Emma Concetta Manno (EC)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Gioacchino Andrea Rotulo (GA)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Carolina D'Anna (C)

Cardiology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Marcello Chinali (M)

Cardiology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Isabella Tarissi de Jacobis (IT)

Emergency, Acceptance and General Pediatrics Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Danilo Buonsenso (D)

Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Centro di Salute Globale, Università Cattolica del Sacro Cuore, Rome, Italy.

Alberto Villani (A)

Chair of Pediatrics, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Emergency, Acceptance and General Pediatrics Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Paolo Rossi (P)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Alessandra Marchesi (A)

Emergency, Acceptance and General Pediatrics Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Paolo Palma (P)

Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Electronic address: paolo.palma@opbg.net.

Classifications MeSH